
Allogeneic CAR T-Cell Therapy CT0596 Yields Preliminary Efficacy and Safety in R/R Myeloma
The allogeneic, BMCA-targeted CAR T-cell therapy CT0596 displayed a favorable safety profile and generated preliminary efficacy signals in patients with relapsed/refractory multiple myeloma, according to data from an early phase 1 trial (NCT06718270).1 …